Table 3 Meta-regression of VCE retention rate

Study period midpoint^b

− 0.34 (− 0.53 to − 0.14)

245

.0006

− 0.24 (− 0.46 to − 0.02)

245

.0348

Study design

 RCT

Reference

25

Reference

–

–

–

 Prospective

− 0.49 (− 3.36 to 2.38)

115

.7382

–

–

–

 Retrospective

1.05 (− 1.71 to 3.81)

149

.4559

–

–

–

Study region

 Asia

Reference

106

Reference

–

–

–

 Europe

− 1.31 (− 2.93 to 0.31)

120

.1125

–

–

–

 North America

− 0.64 (− 2.71 to 1.43)

50

.5464

–

–

–

 Oceania

0.52 (− 4.56 to 5.61)

7

.8402

–

–

–

 Multiple

− 2.31 (− 6.85 to 2.24)

6

.3195

–

–

–

Patient groups

 Population-based

Reference

160

Reference

Reference

160

Reference

 Known IBD^b

3.07 (0.53 to 5.61)

30

.0176

4.29 (1.46 to 7.12)

30

.0029

 OGIB

1.43 (− 0.30 to 3.17)

67

.1058

–

–

–

 Abdominal pain or diarrhea

4.19 (− 0.73 to 9.11)

6

.0948

3.14 (− 1.75 to 8.04)

6

.2084

 Suspected IBD

1.49 (− 3.31 to 6.28)

9

.5432

–

–

–

 NSAIDs users

− 4.62 (− 10.16 to 0.92)

5

.1020

–

–

–

 Mixed high-risk group

− 0.90 (− 5.40 to 3.61)

7

.6966

–

–

–

 Suspected tumor

− 3.12 (− 8.83 to 2.59)

5

.2847

–

Male

− 3.37 (− 9.99 to 3.25)

261

.3186

–

–

–

Mean age

− 0.02 (− 0.09 to 0.04)

219

.5238

–

–

–

VCE type

 SBCE

Reference

217

Reference

Reference

217

Reference

 After PCE^b

− 4.43 (− 7.67 to − 1.18)

15

.0074

− 5.04 (− 8.75 to − 1.33)

15

.0077

 CCE

− 2.98 (− 5.68 to − 0.29)

26

.0297

− 2.60 (− 6.06 to 0.86)

26

.1401

 ECE

− 3.66 (− 7.02 to − 0.31)

18

.0323

− 3.90 (− 9.05 to 1.26)

18

.1390

 GCE

− 2.82 (− 6.31 to 0.68)

13

.1139

–

–

–